The biggest item this week: a Texas 503A pharmacy recalled compounded glutathione injection nationwide for possible elevated endotoxin, after two patients needed emergency care following IV administration. If your IV or wellness menu includes glutathione, check your lot numbers before you read anything else.
Covers September 26 to October 5, 2026. Every item links to the agency document it comes from.
1. Compounded glutathione recalled for possible elevated endotoxin
On October 1, 2026, FDA posted a voluntary nationwide recall by Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas. The product is compounded glutathione injection, 200 mg/mL, in 10 mL multidose vials “intended for subcutaneous injection.” It was distributed to patients nationwide between June 26 and September 21, 2026. The firm has received two reports of patients who needed emergency department care after IV administration of a glutathione product “that was not formulated for IV use.” The notice warns that injectables with elevated endotoxin “could cause significant medical events including fevers, hypotension, inflammatory reactions, anaphylactic shock and death.” Ten lots are listed, with expiration dates from October 2 to November 12, 2026.
What to do: pull every glutathione vial on site and in patient hands, match lot numbers against the FDA notice, and confirm that your IV protocol never routes a product intended for subcutaneous injection into a line. IV therapy oversight.
Source: FDA recall notice, Greenwich Rx
2. FDA warns an online seller of unapproved botulinum toxin
On September 14, 2026, FDA issued a warning letter to Celmade (MARCS-CMS 735876), posted September 29. The firm offered injectable botulinum toxin products, including “Wonder tox 100,” to U.S. consumers through celmade.co and celmade.net. FDA cites sections 301(a), 301(d), 502(f)(1), 503(b)(1) and 505(a) of the FD&C Act. The letter points to the boxed warning on distant spread of toxin effect, where “swallowing and breathing difficulties can be life threatening,” and notes that drugs outside regulatory safeguards “may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether.”
What to do: buy neurotoxin only from the manufacturer or its authorized distributor, keep the invoice with the lot number, and treat any “same product, lower price” offer as a counterfeit until proven otherwise. Aesthetics and injectables oversight.
Source: FDA warning letter 735876
3. Federal charges over counterfeit Ozempic sold into the U.S. supply
On September 29, 2026, FDA announced charges of conspiracy and smuggling, brought in the Middle District of Florida, in a scheme that sent counterfeit Ozempic (semaglutide) to distributors in the United States between July 2023 and April 2024. FDA says the fake pens, labels, inserts and needles were “meant to deceive downstream customers, including pharmacies and patients,” and that distribution continued after FDA’s December 2023 seizure and public warning.
What to do: if your weight-management program dispenses or administers branded GLP-1 pens, document where every pen came from and stop buying from any source that cannot show a chain back to the manufacturer. Weight management programs.
Source: FDA press announcement
4. DEA revokes a pharmacy registration over red flags and missing inventory
On October 2, 2026, DEA published a decision revoking the registration of St. Michael’s Pharmacy, effective November 2, 2026 (FR Doc. 2026-20227). DEA found the pharmacy filled controlled substance prescriptions “without addressing or resolving red flags of abuse,” citing 21 CFR 1306.04(a) and Texas pharmacy rules. The red flags included pattern prescribing, highest-strength doses in large quantities, patients getting similar drugs from several practitioners, and patients at shared addresses. An audit found more than 73,000 dosage units unaccounted for.
What to do: if you run a pharmacy that fills controlled substance orders from clinic or telehealth prescribers, document how each red flag was resolved before the fill, and reconcile inventory on a schedule you can show an investigator. Pharmacies and labs.
Source: Federal Register 2026-20227
What this means for you
Three of this week’s four items are about where a product came from and whether you can prove it. A recalled lot, a gray-market toxin and a counterfeit pen all reach a patient through a purchase decision someone in your clinic made. Pick one injectable you buy most often and trace a single vial back to its invoice, its lot and its source this week. If that chain has a gap, book a call and we will review your sourcing with you.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.